here. >> good morning, martha. martha: this is durb, they does tk* this study, they compared it to actos, did the study 11 years ago and during that study found out it was risky to the heart an there's an e-mail from a dr. marketten fried that says these data should not see the light of day. >> very shocking. this is an accumulating problem with this particular manufacturer, and this drug. over a ten-year period, involving at least six clinical trials, actos, you mentioned, i want to give the background on this, there's a class of drugs, there are three drugs in the class, one was removed from the market ten years ago, resyly -- reslyn for causing liver problems. these have been under scrutiny ever since. these drugs are great, they allow a diabetic to get rid of excess sugar. diabetes triples your risk of heart disease, stroke so you can imagine we want to drug but over the past ten years we have more drugs we
Related Keywords
Martha Maccallum , Heart , Study , Pactos , Durb , E Mail , 11 , Drug , Dr , Problem , Trials , Manufacturer , Data , Flight , Marketten Fried , Six , Ten , One , Drugs , Class , Market , Liver Problems , Background , Reslyn , Resyly , Three , Risk , Diabetic , Diabetes , Heart Disease , Scrutiny , Excess Sugar ,
comparemela.com © 2020. All Rights Reserved.